Placeholder Banner

BIO Submits Amicus Brief in Sandoz Inc. v. Amgen Manufacutring Inc. and Amgen Manufacturing Ltd v. Sandoz Inc. (U.S. Supreme Court)

March 17, 2017

BIO submitted an amicus brief in Sandoz Inc. v. Amgen Inc. and Amgen Manufacturing Limited, as well as Amgen Inc. and Amgen Manufacturing Limited v. Sandoz Inc., at the Supreme Court of the United States.

As one of the leading proponents for the creation of a biosimilar approval pathway that also maintains incentives for innovation, BIO has a strong interest in the proper implementation of this statutory scheme by the courts.

Related Resources
15-1039-15-1195-bsac-Biotechnology-Innovation-Organization 0
BIO Amgen v. Sandoz Brief (SCOTUS)
Discover More
BIO has filed an amicus brief in U.S. ex rel. Scutte v. SuperValu Inc., which addresses the issue of the intent requirement under the False Claims Act (FCA). Specifically, BIO urges the Court to uphold the view that a firm does not…
The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge a District Court’s unprecedented ruling (related to a single drug known as mifepristone) that would create regulatory barriers and potentially upend FDA’s…
BIO and AUTM have filed an amicus brief in petition for a writ of certiorari the in American Axle & Manufacturing, Inc., v. Neapco Holdings LLC, et al., at the Supreme Court of the United States. BIO and AUTM are concerned that…